Life Science Partnering
If you are a biotech company looking for a way to convey your innovation strategy to potential partners and investors, consider the presenting company track at BioPharm America™ 2014 in Boston. The deadline to apply to present is Monday, July 7.
Presenting companies are divided into four distinct tracks. The Biotech company presentation track showcases biotech companies that seek to partner their products, initiate strategic alliances or tap into the international financing network.
The Midsize Pharma presentation track was truly built by demand, and has been continuously increasing as midsize pharma companies move toward more collaborative approaches in their business strategies.
The Next Generation presentation track features early stage projects and small entrepreneurial companies that have advanced from academia into an innovation setting.
And finally, the Academic Innovators™ presentation track features academic researchers and technology transfer offices presenting their project to potential investors.
There are just a few days left to apply for your presentation slot. Apply at: http://bit.ly/1lX2aMU
By now you have probably heard about yesterday’s issuance by the FDA of draft guidelines that require manufacturers to include risk information when posting on social media. Also issued were FDA guidelines on how drug and device manufacturers should respond to misinformation about their products, either on their own social media or on independent third-party websites, social media and blogs.
You can read more about it at: http://1.usa.gov/1nPajCF
The guidelines are the FDA’s way to ensure that public health is protected by providing timely and accurate information on drug safety information and contraindications. What it boils down to is, if you are a drug or device manufacturer, and you decide to make a social post about a benefit of one of your products, you are required to list the most serious risks and and a link for more information in the same message or Tweet.
This could really cramp the style of a lot of social media staff at pharma companies, for starters. Just considering the 140 character limit of Twitter posts, it is already difficult to convey clear and concise information that is also compelling and interesting.
We would love to hear your opinion on how this will affect your company, in particular. Add your comments.
BIO14 in San Diego is just one week away, and no doubt planning your schedule is a top priority. Here are some tips on how you can use partnering360 to open a dialogue with your current contacts and potential prospects or partners, and add depth to your partnering activity on-site.
1. Post a message to your partnering360 wall, and share with your LinkedIn and Twitter networks that you will be at BIO14;
2. Research your prospective partners on partnering360, watch their videos and check out their assets;
3. Can't find someone at BIO? Connect via partnering360 to ask if they are attending;
4. Create a post in the Life Science Partnering group to instantly reach 24,000 people with your BIO14 takeaways.
As well, partnering360 staff will be at Booth 1630 to provide you with personal assistance and to show you new features on the premier network for dealmakers in the life science industry. And we have a fun giveaway for you. See you soon!
The Scoop: H.R. 4800 is the FY15 appropriations bill that would provide funds for the various Department of Agriculture (USDA) programs and services, including $20 million in salaries and expenses for the FDA Office of the Commissioner.
Why it matters: In the bill, the FDA's decisions on prescription drug approvals receive scrutiny, as do the Food Safety and Inspection Service's plans for using modern science and improving public health. The bill undermines key investments in financial oversight and politicizes progress on science-based nutrition standards, as well. The $20 million appropriation will be withheld unless certain deadlines are met, which would restrict staff and resources at the FDA and could have far-reaching negative impacts on the FDA's public health mission.
What the White House said: The Executive office said that if the President were presented with H.R. 4800, “his senior advisors would recommend that he veto the bill.” The Administration also states that it “strongly opposes provisions that unduly interfere with FDA's rulemaking process.”
What’s next: Basically, the bill states that the FDA must publish final guidance for the development of abuse-deterrent opioids by June 30, 2015, or the appropriated $20 million would go to the FDA's Office of Criminal Investigation to combat illegal sales of controlled substances. The Administration said the FDA is working on it. Discussions are ongoing.
Statement of Administration policy opposing the bill: http://www.whitehouse.gov/sites/default/files/omb/legislative/sap/113/saphr4800r_20140610.pdf
Read about H.R. 4800: http://beta.congress.gov/bill/113th-congress/house-bill/4800 and http://beta.congress.gov/113/bills/hr4800/BILLS-113hr4800rh.pdf
Last year alone the biotech sector faced a hard 2013 with more than 22,000 layoffs. Genetic Engineering and Biotech News shares that the challenges will keep coming and include the rising costs of healthcare reform, patent cliff losses and more. However, jobs in the sector will continue to grow.
The top jobs according to the article are:
9. Genetic Counselors
8. Zoologists and Wildlife Biologists
6. Biomedical Engineers
5. Biochemists and Biophysicists
4. Chemical Technicians
What are the top 3? Head over to the Genetic Engineering and Biotechnology News article to find out: http://bit.ly/1l3Rjjv